Literature DB >> 11593176

Globe sparing orbital exenteration.

P J Catalano1, D Laidlaw, C Sen.   

Abstract

OBJECTIVE: Orbital exenteration has long been the oncologic standard for malignant craniofacial lesions that invade the periorbita/orbit from adjacent locations. Although oncologically sound, this radical surgical procedure is cosmetically disfiguring for all patients. Most of the reconstructive options available are complex, requiring further surgery and/or expense. We herein introduce an alternative surgical technique for radical orbital surgery that spares the globe, thereby allowing an early, aesthetic appearance at a nominal cost. STUDY DESIGN AND
SETTING: Twenty consecutive patients requiring an oncologic orbital exenteration and meeting the indications for the new procedure underwent surgery at a tertiary care medical center. Follow-up ranged from 1 to 6 years.
RESULTS: Only 1 patient recurred in the orbit due to an error in patient selection. There was no surgical morbidity resulting from the globe-sparing technique itself.
CONCLUSION: Globe-sparing orbital exenteration is a one-step, oncologically sound, aesthetically superior, low-cost alternative for those patients requiring radical orbital surgery and reconstruction.

Entities:  

Mesh:

Year:  2001        PMID: 11593176     DOI: 10.1067/mhn.2001.118247

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

Review 1.  Considerations in Orbital Exenteration.

Authors:  Mofiyinfolu Sokoya; Jason E Cohn; Scott Kohlert; Thomas Lee; Sameep Kadakia; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2019-04-26       Impact factor: 2.314

2.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.